下载掌阅APP，畅读海量书库
立即打开
［1］黄燕如，唐浩熙，刘红伟，等. 132例输血不良反应病例回顾性分析［J］. 检验医学与临床，2019，16（13）：1840-3.
［2］李德应，王玉明，柴华香，等. 218例输血不良反应的回顾性分析及预防策略［J］.昆明医科大学学报，2019；40（11）：59-62.
［3］张勇. 不同血液制品在临床应用中引起的不良反应分析［J］. 智慧健康，2019，5（03）：80-1+4.
［4］黄爱群，孙凯，陈惠红，等. 输血不良反应的发生率及相关影响因素［J］. 实用医学杂志，2020，36（12）：1665-8.
［5］唐聪海，黄燕雪，林艺璇，等. 输血不良反应相关因素分析［J］.中国实验血液学杂志，2020；28（03），972-6.
［6］吴李萍，罗敏，李红霞. 某三甲医院131例次输血不良反应回顾性分析. ［J］检验医学与临床，2020，17（06）：724-7.
［7］HEDDLE NM，BLAJCHMAN MA，MEYER RM，et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets［J］. Transfusion，2002，42（5）：556-566.
［8］HEDDLE NM，KLAMA L，MEYER R，et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets［J］. Transfusion，1999，39（3）：231-238.
［9］HEDDLE NM. Pathophysiology of febrile nonhemolytic transfusion reactions［J］. Current opinion in hematology，1999，6（6）：420-426.
［10］VAMVAKAS EC. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions［J］. Transfusion medicine reviews，1998，12（4）：258-270.
［11］WANG RR，TRIULZI DJ，QU L. Effects of prestorage vs poststorage leukoreduction on the rate of febrile nonhemolytic transfusion reactions to platelets［J］. American journal of clinical pathology，2012，138（2）：255-259.
［12］NAHIRNIAK S，SLICHTER SJ，TANAEL S，et al. Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia［J］. Transfusion medicine reviews，2015，29（1）：3-13.
［13］SEED CR，WONG J，POLIZZOTTO MN，et al. The residual risk of transfusion-transmitted cytomegalovirus infection associated with leucodepleted blood components［J］. Vox Sang，2015，109（1）：11-17.
［14］STEC N，KICKLER TS，NESS PM，et al. Effectiveness of leukocyte（WBC）depleted platelets in preventing febrile reactions in multitransfused oncology patients（abstract）［J］.Transfusion，1986，26：569.
［15］KICKLER TS，BELL W，NESS PM，et al. Depletion of white cells from platelet concentrates with a new adsorption filter［J］. Transfusion，1989，29：411-414.
［16］CHAMBERS LA，KRUSKALL MS，PACINI DG. Donovan LM. Febrile reactions after platelet transfusion：the effect of single versus multiple donors［J］. Transfusion，1990，30：219-221.
［17］DAN ME，STEWART S . Prevention of recurrent febrile transfusion reactions using leukocyte poor platelet concentrates prepared by the“Leukotrap”centrifugation method（abstract）［J］. Transfusion，1986，26：569.
［18］BRAND A，CLAAS FH，VOOGT PJ，et al. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions［J］. Vox Sang，1988，54：160-166.
［19］VAN MANVIJK KOOY M，VAN PROOIJEN HC，MOES M，BOSMASTANTS I，et al. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization：a prospective，randomized trial［J］. Blood，1991，77：201-205.
［20］EISENFELD L. SILVER H，MCLAUGHLIN J，et al. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood［J］.Transfusion，1992，32：205-209.
［21］SMITH KL，COBAIN T，DUNSTAN RA. Removal of cytomegalovirus-DNA from donor blood by filtration［J］. Br J Haematol，1993，83：640-642.
［22］JENSEN LS. ANDERSEN AJ，CHRISTIANSEN PM，et al. Postoperative infection and natural killer cell function folldwing blood transfusion in patients undergoing elective colorectal surgery［J］. Br J Surg，1992，79：513-516.
［23］GIANOTTI L，PYLES T. ALEXANDER JW，Fukushima R，Babcock GF. Identification of the blood component responsible for increased susceptibility to gut-derived infection［J］.Transfusion，1993，33：458-465.
［24］ANDERSON KC，WEINSTEIN KIJ. Transfusion-associated graft-versus-host disease［J］.N Engl J Med，1990，323：315-321.
［25］PERKINS HA. Is white cell reduction cost-effective?（editorial）［J］. Transfusion，1993，33：626-628.
［26］DZIK WH. Leukoreduced blood components：“You can filter now or you can filter later.”［J］.Transfus Sci，1992，13：207-210.
［27］BALDUCCI L，BENSON K，LYMAN GH，et al. Cost-effectiveness of white cell-reduction filters in the treatment of adult acute myelogenous leukemia［J］. Transfusion，1993，33：665-670.
［28］DZIK WH，CUSACK WF，GALEK MJ. Preparation of white cell-reduced platelet concentrates from whole blood during component preparation［J］. Transfusion，1991，31：542-546.
［29］MUYLLE L，JOOS M，WOUTERS E，et al. Increased tumor necrosis factor a（TNFa），interleukin I，and interleukin 6（IL-6）levels in the plasma of stored platelet concentrates：relationship between TNF a and IL-6 levels and febrile transfusion reactions［J］.Transfusion，1993，33：195-199.
［30］HEDDLE NM，KLAMA L，MEYER R，et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets［J］. Transfusion，1999，39：231-238.